Streetbeat News

PRFX

PainReform Ltd.

https://www.painreform.com

Industry

Drug Manufacturers - Specialty & Generic

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

PainReform Ltd. has confirmed the optimal delivery method for its product PRF-110 in bunionectomy procedures, highlighting its superior coverage and stability in surgical wounds. This positions PRF-110 as a competitive post-surgical pain management solution.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:34 pm

RainReform shares increased following the announcement of positive early safety results from its Phase 3 Bunionectomy study of PRF-110.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 12:40 pm

PainReform has announced early safety results from its Phase 3 bunionectomy study of PRF-110, showing a low incidence of adverse events, averaging just one per subject.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 12:31 pm

PainReform reported R&D expenses of $11.4M for H1 2024 due to a Phase 3 trial, resulting in a net loss of $12.8M. G&A expenses decreased to $1.5M, and the cash position is at $2.8M following a $4M public offering in April.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:14 pm

PainReform Ltd. (NASDAQ:PRFX) has announced the successful development and manufacturing of new patented formulations of its extended postoperative pain relief therapy, PRF-110. These formulations incorporate both an analgesic and an anti-inflammatory agent, designed to enhance postoperative recovery and reduce opioid reliance.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 1:03 pm

PainReform announced safety data for its PRF-110 product, revealing that maximum blood levels are at 10% of the FDA safety threshold.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 2:01 pm

PainReform Ltd. (NASDAQ:PRFX) announced that its lead asset, PRF-110, promoted normal wound healing and prevented scar formation following surgical procedures. The company is on track to report top-line results from its Phase 3 trial in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 1:03 pm

PainReform Ltd. (NASDAQ:PRFX) has announced a significant advancement in the development of its lead asset, PRF-110. The company has developed a new manufacturing process that allows PRF-110 to remain stable for 18 months at room temperature, a major milestone for the clinical-stage specialty pharmaceutical company.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:39 pm

PainReform has filed a patent for a highly scalable manufacturing process for its PRF-110 product, which could enhance production efficiency and potentially reduce costs.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 12:32 pm

On June 24, PainReform announced that Ilan Hadar, the CEO and CFO, has ceased his service to the company. Ehud Geller has been appointed as the interim CEO and CFO, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.